Medroxyprogesterone Acetate
Brand names: Medroxyprogesterone Acetate, Depo-Subq Provera 104
At a glance
- Medicare prescriptions, 2024
- 184,312
- Medicare drug cost
- $3.8M
- Average cost per prescription
- $20.53
- Clinicians who prescribed it
- 8,387
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia.) The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders. ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study reported an…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- OB-GYN (Obstetrics & Gynecology) 39.3%
- Family Medicine 18.8%
- Nurse Practitioners 15.0%
- Internal Medicine 12.4%
- Physician Assistants 2.9%
- Geriatric Medicine 2.0%
- Psychiatry 2.0%
- Psychiatric Nurse Practitioners 1.6%
- Gynecologic Oncology 0.8%
- General Practice 0.8%
- Certified Nurse-Midwives 0.8%
- Endocrinology & Diabetes 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 11% from 2019 to 2024.
Biggest change by state since 2019
- Georgia +2%
- Arkansas −2%
- Oklahoma −3%
- Iowa −3%
- Alabama −4%
- Colorado (smallest change) −28%
- California (smallest change) −26%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white round tablet, 7 mm, scored to split in 2 | 555 779 B |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | white round tablet, 6 mm, scored to split in 2 | 555 872 B |
Pharmacia & Upjohn Company LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | orange round tablet, 6 mm, scored to split in 2 | PROVERA 2 5 |
| 5 mg | blue round tablet, 6 mm, scored to split in 2 | PROVERA 5 |
| 10 mg | white round tablet, 7 mm, scored to split in 2 | PROVERA 10 |
Preferred Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | white round tablet, 6 mm, scored to split in 2 | 555 873 B |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | white round tablet, 6 mm, scored to split in 2 | 555 873 B |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Dec 2024 · Eugia US LLC · Class II
CGMP Deviations - May 2022 · Sun Pharmaceutical Industries Inc · Class II
Lack of assurance of sterility
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.